Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut ...